The Pharmaceutical Market: USA
THE PHARMACEUTICAL MARKET: USA - REVIEW
Espicom projects that the US pharmaceutical market will grow by a moderate CAGR between 2011 and 2016. The effect of recent legislation is difficult to measure. Pharmaceutical companies face a number of costs initially, depressing sales growth. However, pharmaceutical sales are expected to be boosted in the long-term as at least an additional 32.0 million Americans, equal to about a tenth of the population, should receive insurance from 2014 onwards. Not all of this additional population will require drugs, as many will be young people or those already consuming drugs, but further consumption should rise overall. Biologic companies will gain with the new 12-year data exclusivity provided by the new healthcare regulation. In 2011, major competitive strategies included Novo Nordisk’s agreement to set up a new US headquarters; Pfizer’s sale of Capsugel to KKR; Allergan’s agreement to acquire all of the outstanding assets of Vicept; Valeant’s agreement to acquire the assets of Janssen’s Ortho Dermatologics division; Valeant’s agreement to acquire Dermik from Sanofi; Merck & Co’s acquisition of Inspire; Baxter’s agreement to acquire Prism Pharmaceuticals; Forest’s acquisition of Clinical Data (CD); Sanofi’s acquisition of Genzyme; Daiichi Sankyo’s acquisition of Plexxikon; AstraZeneca’s US$1.1 billion payment to resolve tax matters; and Pfizer’s acquisition of King Pharmaceuticals.
The US generic sector is expected to rise by a higher CAGR between 2011 and 2016. According to the GPhA, there are around 50 manufacturers. Major US generic players include Mylan, Watson and Hospira. Other important US generic companies include Greenstone (Pfizer), Qualitest Products and Mallinckrodt. Overseas companies have a major stake in the market, including Teva, Sandoz (Novartis), Apotex, Actavis, Lupin and Dr Reddy’s. A number of other Indian companies are attempting to break into the retail market. In 2011, major competitive strategies included KV’s divestidure of Nesher Pharmaceuticals; Perrigo’s acquisition of Paddock Laboratories; Cephalon shareholders’ approval for Teva to acquire the company; Watson’s announcement to expand its Salt Lake City site; the merger of Caraco and Sun; Apotex’s resumed shipments to the USA; Hikma’s acquisition of Baxter's Generic Injectables Business; Sagent’s IPO launch; Texas Jury’s order for Actavis to pay US$170.3 million in damages; and Elite’s generic agreement with Hi-Tech Pharmacal.
In May 2011, the FDA published details of its proposed user fee structure for the regulation of biosimilar products in the USA. This would run for five years, from 2013 to 2017. Under the Biologics Price Competition and Innovation Act (BCPIA), the FDA has been given the task of developing such a user fee programme in order to support its activities in the area. The BCPIA creates a new category of approval – a 351(k) – for biosimilars under the Public Health Service Act (PHS). To date, all existing biologics are approved under the 351(a) procedure, for which user fees are already collected under the Prescription Drug User Fee Act (PDUFA), first enacted in 1993. Fees are currently collected for all original drug and biologic applications, but not for ANDA generic applications. In 2011, major competitive strategies included Gilead’s agreement to purchase one of Genentech's manufacturing facilities; Omni Bio’s stake acquisition in BioMimetix; Grifols’ acquisition of Talecris Biotherapeutics; Astellas’ acquisition of Perseid from Maxygen; Sanofi’s acquisition of Genzyme; Boehringer Ingelheim’s acquisition of Amgen's Fremont facility; Amgen’s acquisition of BioVex; Gilead’s acquisition of Calistoga Pharmaceuticals; the alliance between Merck and Parexel to form a biosimilar strategic alliance; Alexion’s acquisition of Taligen; and Eli Lilly’s agreement to acquire Alnara Pharmaceuticals.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
GLOBAL COMPANY INTELLIGENCE
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Espicom projects that the US pharmaceutical market will grow by a moderate CAGR between 2011 and 2016. The effect of recent legislation is difficult to measure. Pharmaceutical companies face a number of costs initially, depressing sales growth. However, pharmaceutical sales are expected to be boosted in the long-term as at least an additional 32.0 million Americans, equal to about a tenth of the population, should receive insurance from 2014 onwards. Not all of this additional population will require drugs, as many will be young people or those already consuming drugs, but further consumption should rise overall. Biologic companies will gain with the new 12-year data exclusivity provided by the new healthcare regulation. In 2011, major competitive strategies included Novo Nordisk’s agreement to set up a new US headquarters; Pfizer’s sale of Capsugel to KKR; Allergan’s agreement to acquire all of the outstanding assets of Vicept; Valeant’s agreement to acquire the assets of Janssen’s Ortho Dermatologics division; Valeant’s agreement to acquire Dermik from Sanofi; Merck & Co’s acquisition of Inspire; Baxter’s agreement to acquire Prism Pharmaceuticals; Forest’s acquisition of Clinical Data (CD); Sanofi’s acquisition of Genzyme; Daiichi Sankyo’s acquisition of Plexxikon; AstraZeneca’s US$1.1 billion payment to resolve tax matters; and Pfizer’s acquisition of King Pharmaceuticals.
The US generic sector is expected to rise by a higher CAGR between 2011 and 2016. According to the GPhA, there are around 50 manufacturers. Major US generic players include Mylan, Watson and Hospira. Other important US generic companies include Greenstone (Pfizer), Qualitest Products and Mallinckrodt. Overseas companies have a major stake in the market, including Teva, Sandoz (Novartis), Apotex, Actavis, Lupin and Dr Reddy’s. A number of other Indian companies are attempting to break into the retail market. In 2011, major competitive strategies included KV’s divestidure of Nesher Pharmaceuticals; Perrigo’s acquisition of Paddock Laboratories; Cephalon shareholders’ approval for Teva to acquire the company; Watson’s announcement to expand its Salt Lake City site; the merger of Caraco and Sun; Apotex’s resumed shipments to the USA; Hikma’s acquisition of Baxter's Generic Injectables Business; Sagent’s IPO launch; Texas Jury’s order for Actavis to pay US$170.3 million in damages; and Elite’s generic agreement with Hi-Tech Pharmacal.
In May 2011, the FDA published details of its proposed user fee structure for the regulation of biosimilar products in the USA. This would run for five years, from 2013 to 2017. Under the Biologics Price Competition and Innovation Act (BCPIA), the FDA has been given the task of developing such a user fee programme in order to support its activities in the area. The BCPIA creates a new category of approval – a 351(k) – for biosimilars under the Public Health Service Act (PHS). To date, all existing biologics are approved under the 351(a) procedure, for which user fees are already collected under the Prescription Drug User Fee Act (PDUFA), first enacted in 1993. Fees are currently collected for all original drug and biologic applications, but not for ANDA generic applications. In 2011, major competitive strategies included Gilead’s agreement to purchase one of Genentech's manufacturing facilities; Omni Bio’s stake acquisition in BioMimetix; Grifols’ acquisition of Talecris Biotherapeutics; Astellas’ acquisition of Perseid from Maxygen; Sanofi’s acquisition of Genzyme; Boehringer Ingelheim’s acquisition of Amgen's Fremont facility; Amgen’s acquisition of BioVex; Gilead’s acquisition of Calistoga Pharmaceuticals; the alliance between Merck and Parexel to form a biosimilar strategic alliance; Alexion’s acquisition of Taligen; and Eli Lilly’s agreement to acquire Alnara Pharmaceuticals.
ENHANCED STRATEGIC INTELLIGENCE
Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:
- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.
HEALTHCARE STATISTICS
A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.
HIGHLY DETAILED REPORT CONTENT
EXECUTIVE SUMMARY
Including Espicom's at a glance strategic analysis and key data projections
MACROENVIRONMENT
Political, economic, legal and demographic analysis
EPIDEMIOLOGY
Disease burden and prevalence
HEALTHCARE
Organisation, expenditure, infrastructure, services and workforce
REGULATORY AFFAIRS
Regulatory developments and marketing registration/authorisation
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET ANALYSIS
Projections, product development, manufacturing and trade
COMPETITION
Trade associations, trade fairs, company intelligence and competitive strategies
GLOBAL COMPANY INTELLIGENCE
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
OPPORTUNITIES & CHALLENGES
Espicom's unique strategic analysis
DIRECTORY
METHODOLOGY & SOURCES
Contents
EXECUTIVE SUMMARYA patent reform is in discussion to strengthen IPR protection. 1
Snapshot: Strategic Espicom Analysis
Snapshot: Key Data Projections
MACROENVIRONMENT
POLITICAL
ECONOMIC
Projections
LEGAL
Intellectual Property Rights
2011 Patent Law Reform
Hatch-Waxman Reform
Hatch-Waxman
Bolar Amendment
DEMOGRAPHIC
Projections
Demographic Indicators
Birth Rate
Death Rate
Infant Mortality
Life Expectancy at Birth
EPIDEMIOLOGY
DISEASE BURDEN
DISEASE PREVALENCE
Communicable Diseases
HIV/AIDS
Non-Communicable Diseases
HEALTHCARE - ACCOMPANYING HEALTH STATISTICS
ORGANISATION
Passage of the Healthcare Reform
Centres for Medicare & Medicaid Services
Medicare
Medicaid
CHIP
Health Insurance Portability and Accountability Act of 1996
Private Health Provision
Blue Cross and Blue Shield Association (BCBSA)
Managed Care
EXPENDITURE
Projections
INFRASTRUCTURE
Hospital Resources
SERVICES
Inpatient Activity Analysis
Outpatient Activity Analysis
WORKFORCE
Projections
REGULATORY AFFAIRS
NATIONAL AUTHORITY
FDA Amendments Act (FDAAA)
FDA Modernization Act
DRUG APPROVAL PROCESS
Preclinical Assessment
Clinical Trials
FDA Review
Post-Marketing Surveillance
Drug Recalls
GOOD MANUFACTURING PRACTICE ENFORCEMENT
MARKETING
Direct-to-Consumer Promotion
FDAAA Modifications to DTC Promotion
INTERNATIONAL CO-OPERATION
Information-Sharing Agreements
European Medicines Agency
Japan and Australia
Mexico and Canada
Switzerland
Harmonisation
PRICING & REIMBURSEMENT
PUBLIC DRUG PROCUREMENT
Medicaid
Average Wholesale Price (AWP)
Medicare
Bill H.R.1
STATE PRICING/REIMBURSEMENT MOVES
DISTRIBUTION CHANNELS
WHOLESALING
Trade Association
HDMA
Leading Wholesalers
AmerisourceBergen
Cardinal Health
McKessons Corporation
RETAILING
Trade Association
NACDS
Leading Drug Store Chains
CVS Caremark
Walgreens
MARKET ANALYSIS
SIZE
Projections
Historical Figures
Current Structure
Prescription Drug Sales by Source
Retail Prescription Drug Sales by Retail Type
Retail Drug Store Sales
Research-Based Pharmaceutical Sales
PRODUCT DEVELOPMENT
MANUFACTURING
TRADE
Exports
Imports
Parallel Imports
Balance of Trade
COMPETITION
TRADE ASSOCIATION
PhRMA
Competitive Strategies
GLOBAL COMPANY INTELLIGENCE
Abbott
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Allergan
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Amgen
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Biogen Idec
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Bristol-Myers Squibb
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Eli Lilly
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Forest Laboratories
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Gilead Sciences
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Hospira
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Johnson & Johnson
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Merck & Co
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Mylan
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Pfizer
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
Watson Pharmaceuticals
Company Overview
Financial Performance
Product Portfolio
R&D Strategy
Manufacturing Capabilities
Outlook
REGULATORY AFFAIRS
OTC Drug Review
MARKET SIZE
COMPETITION
Trade Association
CHPA
Competitive Strategies
GENERIC PHARMACEUTICALS
REGULATORY AFFAIRS
Generic Drug Review
Ruling regarding Labelling
Push for Generic Drug User Fees
MARKET SIZE
COMPETITION
Trade Association
GPhA
Competitive Strategies
BIOLOGICS & BIOSIMILARS
REGULATION
Biologic Therapeutic Review
Proposed Biosimilar User Fee Structure
Call for Shorter Data Exclusivity Period for Biologics
Biosimilar Hearing
Work on Biosimilar Pathway
Biosimilar Pathway Provisions
PRODUCT DEVELOPMENT
PhRMA Expenditure on Biologics
Qualifying Therapeutic Discovery Project
COMPETITION
Trade Associations
BIO
PPTA
Competitive Strategies
CONCLUSIONS: OPPORTUNITIES & CHALLENGES
Strategic Espicom Analysis
MACROENVIRONMENT
EPIDEMIOLOGY
HEALTHCARE
REGULATORY AFFAIRS
PRICING & REIMBURSEMENT
DISTRIBUTION CHANNELS
MARKET
COMPETITION
OTC PHARMACEUTICALS
GENERIC PHARMACEUTICALS
BIOLOGICS & BIOSIMILARS
Radar Analysis
SWOT Analysis
DIRECTORY
COMPANY INTELLIGENCE
GOVERNMENT ORGANISATIONS
TRADE ORGANISATIONS
METHODOLOGY & SOURCES
LIST OF TABLES
Espicom Analysis of the Pharmaceutical Market, 2011
Key Data Projections, 2011-2016
Political Landscape, 2011
Regional Ranking of Projected Economies, 2016 (US$ Billion)
Projected Economy, 2011-2016 (US$ Billion)
Regional Ranking of Projected Demographics, 2016 (Million)
Projected Demographics, 2011-2016 (Million)
Selected Demographic Indicators, 1990-2009
Causes of Death, 2000-2009 (000s)
Regional Ranking of Projected Health Expenditure, 2016
Projected Health Expenditure, 2011-2016
Projected Health Expenditure by Funding Source, 2010-2020 (US$ Billion)
Regional Ranking of Projected Physicians, 2016 (000)
Projected Physicians, 2011-2016 (000)
Organisation of CDER, 2010
FDA Standard & Priority NDAs and BLAs Approvals, 1997-2010
FDA Standard & Priority NMEs and New BLAs Approvals, 1997-2010
FDA Standard & Priority New or Expanded Use Approvals of Drugs and Biologics, 1997-2007
Drug Recalls by Type, 1997-2007
Average Retail Prescription Price, 2007-2009 (US$)
Average Retail Prescription Price by Income Distribution, 2008-2009
AmerisourceBergen’s Selected Financial Data, 2006-2010 (US$ Million)
Cardinal Health’s Selected Financial Data, 2006-2010 (US$ Million)
McKesson Corporation’s Selected Financial Data, 2007-2011 (US$ Million)
Community Pharmacy Retail Outlets, 2005-2009
Regional Ranking of Projected Pharmaceutical Markets, 2016 (US$ Million)
Projected Pharmaceutical Market at Retail Prices, 2011-2016 (US$ Million)
Projected Pharmaceutical Market at Retail Prices by Sector, 2011-2016 (US$ Million)
Projected Pharmaceutical Market at Retail Prices by Sector, 2011-2016 (%)
Historical Pharmaceutical Market at Retail Prices, 1995-2010 (US$ Million)
Projected Prescription Drug Expenditure by Funding Source, 2010-2020 (US$ Million)
Annual Retail Prescription Drug Sales by Retail Type, 2005-2009 (US$ Billion)
Annual Retail Prescription Drug Sales by Retail Type, 2005-2009 (Million Scripts Dispensed)
Monthly Retail Drug Store Sales, 1992-May 2011 (US$ Million)
Annual Research-Based Pharmaceutical Manufacturers’ Sales, 1990-2010 (US$ Million)
R&D Expenditure, 1990-2010 (US$ Million)
R&D Expenditure by Type, 2006-2009 (US$ Million)
R&D Expenditure by Phase, 2005-2009 (US$ Million)
R&D Personnel by Phase, 2005-2009
Pharmaceutical Exports by Category, 1995-2010 (US$ Millions)
Exports of Raw Materials by Country/Region, 2006-2010 (US$ Millions)
Exports of Antisera & Vaccines by Country/Region, 2006-2010 (US$ Millions)
Exports of Semi-finished Medicaments by Country/Region, 2006-2010 (US$ Millions)
Exports of Retail Medicaments by Country/Region, 2006-2010 (US$ Millions)
Pharmaceutical Imports by Category, 1995-2010 (US$ Millions)
Imports of Raw Materials by Country/Region, 2006-2010 (US$ Million)
Imports of Antisera & Vaccines by Country/Region, 2006-2010 (US$ Million)
Imports of Semi-finished Medicaments by Country/Region, 2006-2010 (US$ Million)
Imports of Retail Medicaments by Country/Region, 2006-2010 (US$ Million)
Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)
Members of PhRMA, 2011
Selected US Pharmaceutical Manufacturers by Pharmaceutical Sales, 2006-2010 (US$ Million)
Abbott’s Principal Operating Results, 2007-2011 (US$ Million)
Abbott’s Revenue by Business Area, 2007-2011 (US$ Million)
Abbott’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Abbott’s Pharmaceutical Sales by Leading Products, 2006-2010 (US$ Million)
Abbott’s Recent Product Approvals, 2011-2012
Abbott’s Principal Pharmaceutical Manufacturing Facilities by Location, 2011
Allergan’s Revenue by Business Area, 2007-2011 (US$ Million)
Allergan’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Allergan’s Revenue by Leading Products, 2007-2011 (US$ Million)
Allergan’s Recent Product Approvals, 2011-2012
Amgen’s Principal Operating Results, 2007-2011 (US$ Million)
Amgen’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Amgen’s Pharmaceutical Sales by Leading Products, 2007-2011 (US$ Million)
Amgen’s Recent Product Approvals, 2011-2012
Amgen’s Major Manufacturing Facilities by Location, 2012
Biogen Idec’s Principal Operating Results, 2007-2011 (US$ Million)
Biogen Idec’s Revenue by Business Area, 2007-2011 (US$ Million)
Biogen Idec’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Biogen Idec’s Pharmaceutical Sales by Leading Products, 2007-2011 (US$ Million)
Biogen Idec’s Recent Product Approvals, 2011-2012
Biogen Idec’s Major Manufacturing Facilities, 2012
BMS’ Principal Operating Results, 2007-2011 (US$ Million)
BMS’ Revenue by Geographic Area, 2008-2011 (US$ Million)
BMS’s Pharmaceutical Sales by Leading Products, 2007-2011 (US$ Million)
BMS’ Recent Product Approvals, 2011-2012
Eli Lilly’s Principal Operating Results, 2007-2011 (US$ Million)
Eli Lilly’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Eli Lilly’s Revenue by Leading Products, 2007-2011 (US$ Million)
Eli Lilly’s Recent Product Approvals, 2011-2012
Eli Lilly’s Major Manufacturing Plants, 2011
Forest’s Principal Operating Results, 2006-2010 (US$ Million)
Forest’s Revenue by Business Area, 2006-2010 (US$ Million)
Forest’s Pharmaceutical Sales by Geographic Area, 2006-2010 (US$ Million)
Forest’s Pharmaceutical Sales by Leading Products, 2006-2010 (US$ Million)
Forest’s Recent Product Approvals, 2010-2011
Forest’s Major Manufacturing Facilities by Location, 2011
Gilead’s Principal Operating Results, 2006-2010 (US$ Million)
Gilead’s Revenue by Geographic Area, 2006-2010 (US$ Million)
Gilead’s Pharmaceutical Revenue by Leading Products, 2006-2010 (US$ Million)
Gilead’s Recent Product Approvals, 2010-2011
Gilead’s Major Manufacturing Facilities by Location, 2011
Hospira’s Principal Operating Results, 2006-2010 (US$ Million)
Hospira’s Revenue by Business Area, 2006-2010 (US$ Million)
Hospira’s Revenue by Geographic Area & Business Area, 2006-2010 (US$ Million)
Hospira’s Major Recent Product Approvals, 2010-2011
Hospira’s Major Manufacturing Facilities by Location, 2011
Johnson & Johnson’s Principal Operating Results, 2006-2010 (US$ Million)
Johnson & Johnson’s Revenue by Business Area, 2006-2010 (US$ Million)
Johnson & Johnson’s Revenue by Geographic Area, 2006-2010 (US$ Million)
Johnson & Johnson’s Pharmaceutical Revenue by Leading Products, 2006-2010 (US$ Million)
Johnson & Johnson’s Recent Product Approvals, 2010-2011
Johnson & Johnson’s Major Manufacturing Facilities by Location, 2011
Merck & Co’s Principal Operating Results, 2007-2011 (US$ Million)
Merck & Co’s Revenue by Business Area, 2007-2011 (US$ Million)
Merck & Co’s Revenue by Geographic Area, 2007-2011 (US$ Million)
Merck & Co’s Revenue by Leading Products, 2007-2011 (US$ Million)
Merck & Co’s Recent Product Approvals, 2011-2012
Mylan’s Principal Operating Results, 2008-2010 (US$ Million)
Mylan’s Revenue by Business Area, 2008-2010 (US$ Million)
Mylan’s Sales by Geographic Area, 2008-2010 (US$ Million)
Mylan’s Pharmaceutical Sales by Leading Therapeutic Area, 2008-2010 (US$ Million)
Mylan’s Manufacturing Facilities by Location, 2011
Pfizer’s Principal Operating Results, 2007-2011 (US$ Million)
Pfizer’s Sales by Business Area, 2008-2011 (US$ Million)
Pfizer’s Sales by Geographic Area, 2008-2011 (US$ Million)
Pfizer’s Sales by Leading Products, 2007-2011 (US$ Million)
Pfizer’s Recent Product Approvals, 2011-2012
Pfizer’s Manufacturing Facilities by Location, 2012
Watson’s Principal Operating Results, 2006-2010 (US$ Million)
Watson’s Revenue by Business Area, 2006-2010 (US$ Million)
Watson’s Pharmaceutical Revenue by Geographic Area, 2008-2010 (US$ Million)
Watson’s Recent Branded Product Approvals, 2010-2011
Watson’s Major Manufacturing Facilities by Location, 2011
OTC Drug Review, 2006-2010
OTC Sales by Category, 2006-2010 (US$ Million)
Members of CHPA, 2011
Generic Drug Review, 2006-2010
Leading Companies by ANDAs Approved, 2010
Leading First Time Generic Product Approvals, 2010
Major Generic Product Approvals, 2001-2009
SWOT Analysis of the Generic Sector, 2011
Biologic Therapeutic Review, 2006-2010
New BLAs Approvals, 2004-2010
Biologic R&D Expenditure by Type, 2006-2009 (US$ Million)
Espicom Analysis of the Pharmaceutical Market, 2011
SWOT Analysis of the Pharmaceutical Market, 2011
LIST OF CHARTS
FDA Review Time of Standard & Priority NDAs and BLAs Approvals, 1997-2008 (Months)
FDA Review Time of Standard & Priority NMEs and New BLAs Approvals, 1997-2008 (Months)
FDA Review Time of Standard & Priority New or Expanded Use Approvals of Drugs and Biologics, 1997-2007 (Months)
Regional Comparison of Top 4 Projected Pharmaceutical Markets at Retail Prices, 2016
Regional Comparison of Projected Pharmaceutical Market Share, 2016 (%)
Historical Pharmaceutical Market at Retail Prices, 1995-2010
Historical & Projected Annual Prescription Drug Expenditure, 1965-2020 (%)
Historical & Projected Annual Prescription Drug Expenditure, 1965-2020 (US$ Billion)
Annual Retail Drug Store Sales, 1992-2010 (US$ Billion)
Annual Domestic Research-Based Pharmaceutical Manufacturers’ Sales, 1971-2010 (US$ Billion)
Change in Annual Domestic Research-Based Pharmaceutical Manufacturers’ Sales, 1971-2010 (%)
Pharmaceutical Exports, 1995-2010 (US$ Millions)
Pharmaceutical Imports, 1995-2010 (US$ Millions)
Balance of Pharmaceutical Trade, 1995-2010 (US$ Millions)
Allergan’s Principal Operating Results, 2007-2011 (US$ Million)
OTC Sales, 1990-2010 (US$ Billion)
Radar Graph of the Pharmaceutical Market, 2011 Skip to top